Summit Therapeutics Inc. (SMMT)
| Market Cap | 13.31B -13.2% |
| Revenue (ttm) | n/a |
| Net Income | -856.09M |
| EPS | -1.12 |
| Shares Out | 797.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,900,930 |
| Open | 16.82 |
| Previous Close | 16.91 |
| Day's Range | 16.59 - 17.50 |
| 52-Week Range | 12.07 - 29.23 |
| Beta | -1.24 |
| Analysts | Buy |
| Price Target | 28.55 (+71.06%) |
| Est. Earnings | Oct 19, 2026 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $28.55, which is an increase of 71.06% from the latest price.
News
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving ...
AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today's Market
AMD was inching higher after announcing an $8.2 billion deal to buy World Labs, with other chip stocks gaining.
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company's progress towards achieving its goal of making a significant difference in th...
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potent...
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential fir...
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, dou...
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Pha...
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) e...
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In ...
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in...
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Su...
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class i...
Summit Therapeutics Earnings Call Transcript: Q2 2026
Ivonescimab continues to demonstrate robust clinical efficacy and safety across global phase III trials, with consistent OS benefit in both Asian and Western populations. Financially, the company maintains a strong cash position and is preparing for a potential U.S. launch pending FDA review.
Summit Therapeutics Earnings release: Q2 2026
Summit Therapeutics released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Summit Therapeutics Quarterly report: Q2 2026
Summit Therapeutics has published its Q2 2026 quarterly earnings report on July 23, 2026.
Summit Therapeutics Slides: Q2 2026
Summit Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clini...
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therap...
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinat...
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featurin...
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progres...
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational P...